Analyst Price Target is $4.67
▲ +576.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $4.67, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 576.33% upside from the last price of $0.69.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Cidara Therapeutics. This Buy consensus rating has held steady for over two years.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.